These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 25856820

  • 1. One-year results from clinical practice of epimacular strontium-90 brachytherapy for the treatment of subfoveal choroidal neovascularization secondary to AMD.
    Zur D, Loewenstein A, Barak A.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):338-43. PubMed ID: 25856820
    [Abstract] [Full Text] [Related]

  • 2. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Avila MP, Farah ME, Santos A, Carla L, Fuji G, Rossi J, Nau J.
    Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL, Soare C, Petrarca C, Simpson A, Neffendorf JE, Petrarca R, Muldrew A, Peto T, Chakravarthy U, Membrey L, Haynes R, Costen M, Steel D, Desai R, MERLOT Study Group.
    JAMA Ophthalmol; 2020 Aug 01; 138(8):835-842. PubMed ID: 32644148
    [Abstract] [Full Text] [Related]

  • 4. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
    Dugel PU, Petrarca R, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.
    Ophthalmology; 2012 Jul 01; 119(7):1425-31. PubMed ID: 22465819
    [Abstract] [Full Text] [Related]

  • 5. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
    Jackson TL, Dugel PU, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA, CABERNET Study Group.
    Ophthalmology; 2013 Aug 01; 120(8):1597-603. PubMed ID: 23490325
    [Abstract] [Full Text] [Related]

  • 6. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration.
    Avila MP, Farah ME, Santos A, Duprat JP, Woodward BW, Nau J.
    Br J Ophthalmol; 2009 Mar 01; 93(3):305-9. PubMed ID: 19019935
    [Abstract] [Full Text] [Related]

  • 7. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results.
    Petrarca R, Dugel PU, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.
    Retina; 2014 May 01; 34(5):874-9. PubMed ID: 24169101
    [Abstract] [Full Text] [Related]

  • 8. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography.
    Petrarca R, Dugel PU, Nau J, Slakter JS, Jaffe GJ, Jackson TL.
    Ophthalmology; 2013 Feb 01; 120(2):328-33. PubMed ID: 23178157
    [Abstract] [Full Text] [Related]

  • 9. Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial.
    Jackson TL, Desai R, Simpson A, Neffendorf JE, Petrarca R, Smith K, Wittes J, Lewis C, Membrey L, Haynes R, Costen M, Steel DH, Muldrew A, Chakravarthy U, Macular Epiretinal Brachytherapy versus Ranibizumab (Lucentis) Only Treatment (MERLOT) Study Group.
    Ophthalmology; 2016 Jun 01; 123(6):1287-96. PubMed ID: 27086023
    [Abstract] [Full Text] [Related]

  • 10. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD.
    Avila MP, Farah ME, Santos A, Kapran Z, Duprat JP, Woodward BW, Nau J.
    Retina; 2009 Feb 01; 29(2):157-69. PubMed ID: 19202425
    [Abstract] [Full Text] [Related]

  • 11. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
    Dugel PU, Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, Binder S, Jackson TL, CABERNET Study Group.
    Ophthalmology; 2013 Feb 01; 120(2):317-27. PubMed ID: 23174399
    [Abstract] [Full Text] [Related]

  • 12. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.
    Retina; 2011 Oct 01; 31(9):1812-8. PubMed ID: 21866073
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina; 2011 Oct 01; 31(9):1841-7. PubMed ID: 21775926
    [Abstract] [Full Text] [Related]

  • 14. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB, Lund-Andersen H, Sander B, Larsen M.
    Am J Ophthalmol; 2013 Jul 01; 156(1):116-124.e1. PubMed ID: 23664150
    [Abstract] [Full Text] [Related]

  • 15. Vitrectomy after anti-VEGF therapy for epiretinal membranes coincident with age-related subfoveal choroidal neovascularization.
    Luttrull JK, Spink C.
    Ophthalmic Surg Lasers Imaging; 2008 Jul 01; 39(6):455-9. PubMed ID: 19065974
    [Abstract] [Full Text] [Related]

  • 16. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.
    Am J Ophthalmol; 2009 May 01; 147(5):831-7. PubMed ID: 19217019
    [Abstract] [Full Text] [Related]

  • 17. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
    Chang W, Garg SJ, Maturi R, Hsu J, Sivalingam A, Gupta SA, Regillo CD, Ho AC.
    Am J Ophthalmol; 2014 Jun 01; 157(6):1250-7. PubMed ID: 24531021
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 May 01; 157(5):1013-21. PubMed ID: 24487050
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.